These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21790298)

  • 21. Time course of treatment effect of OROS® methylphenidate in children with ADHD.
    Armstrong RB; Damaraju CV; Ascher S; Schwarzman L; O'Neill J; Starr HL
    J Atten Disord; 2012 Nov; 16(8):697-705. PubMed ID: 22084448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
    Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder.
    Sinzig J; Döpfner M; Lehmkuhl G; ; Uebel H; Schmeck K; Poustka F; Gerber WD; Günter M; Knölker U; Gehrke M; Hässler F; Resch F; Brünger M; Ose C; Fischer R
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):421-32. PubMed ID: 17822338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
    Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S
    J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921
    [No Abstract]   [Full Text] [Related]  

  • 25. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Silva RR; Muniz R; Pestreich L; Brams M; Mao AR; Childress A; Wang J
    J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):199-208. PubMed ID: 18176337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
    Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S
    Arch Gen Psychiatry; 2003 Feb; 60(2):204-11. PubMed ID: 12578439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Greenhill LL; Findling RL; Swanson JM;
    Pediatrics; 2002 Mar; 109(3):E39. PubMed ID: 11875167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measuring methylphenidate response in attention-deficit/hyperactvity disorder: how are laboratory classroom-based measures related to parent ratings?
    Sonuga-Barke EJ; Coghill D; DeBacker M; Swanson J
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):691-8. PubMed ID: 20035587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A non-interventional study of extended-release methylphenidate in the routine treatment of adolescents with ADHD: effectiveness, safety and adherence to treatment.
    Sobanski E; Döpfner M; Ose C; Fischer R
    Atten Defic Hyperact Disord; 2013 Dec; 5(4):387-95. PubMed ID: 23794192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate.
    Sonuga-Barke EJS; Coghill D; Markowitz JS; Swanson JM; Vandenberghe M; Hatch SJ
    J Am Acad Child Adolesc Psychiatry; 2007 Jun; 46(6):701-710. PubMed ID: 17513982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
    Muniz R; Brams M; Mao A; McCague K; Pestreich L; Silva R
    J Child Adolesc Psychopharmacol; 2008 Jun; 18(3):248-56. PubMed ID: 18582179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study.
    Auiler JF; Liu K; Lynch JM; Gelotte CK
    Curr Med Res Opin; 2002; 18(5):311-6. PubMed ID: 12240794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD.
    Wigal S; Lopez F; Frick G; Yan B; Robertson B; Madhoo M
    Postgrad Med; 2019 Apr; 131(3):212-224. PubMed ID: 30681017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.
    Childress AC; Brams M; Cutler AJ; Kollins SH; Northcutt J; Padilla A; Turnbow JM
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):402-14. PubMed ID: 25692608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
    Simonoff E; Taylor E; Baird G; Bernard S; Chadwick O; Liang H; Whitwell S; Riemer K; Sharma K; Sharma SP; Wood N; Kelly J; Golaszewski A; Kennedy J; Rodney L; West N; Walwyn R; Jichi F
    J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
    Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings.
    Breuer D; Görtz-Dorten A; Rothenberger A; Döpfner M
    Eur Child Adolesc Psychiatry; 2011 Oct; 20 Suppl 2(Suppl 2):S289-96. PubMed ID: 21901413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.
    Pelham WE; Gnagy EM; Chronis AM; Burrows-MacLean L; Fabiano GA; Onyango AN; Meichenbaum DL; Williams A; Aronoff HR; Steiner RL
    Pediatrics; 1999 Dec; 104(6):1300-11. PubMed ID: 10585981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.
    Robb AS; Findling RL; Childress AC; Berry SA; Belden HW; Wigal SB
    J Atten Disord; 2017 Dec; 21(14):1180-1191. PubMed ID: 24874348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.
    Silva RR; Muniz R; Pestreich L; Childress A; Brams M; Lopez FA; Wang J
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):239-51. PubMed ID: 16768632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.